Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 1
1948 8
1949 3
1950 4
1951 4
1952 7
1953 12
1954 6
1955 9
1956 13
1957 18
1958 7
1959 12
1960 13
1961 27
1962 36
1963 80
1964 93
1965 123
1966 104
1967 129
1968 181
1969 165
1970 196
1971 194
1972 194
1973 177
1974 158
1975 188
1976 199
1977 148
1978 150
1979 140
1980 165
1981 155
1982 199
1983 239
1984 231
1985 225
1986 244
1987 230
1988 227
1989 228
1990 235
1991 271
1992 249
1993 241
1994 235
1995 336
1996 326
1997 347
1998 386
1999 399
2000 389
2001 438
2002 414
2003 431
2004 466
2005 499
2006 530
2007 488
2008 466
2009 450
2010 445
2011 472
2012 418
2013 430
2014 459
2015 480
2016 485
2017 464
2018 493
2019 452
2020 438
2021 223
Text availability
Article attribute
Article type
Publication date

Search Results

16,639 results
Results by year
Filters applied: . Clear all
Page 1
Prasterone.
Kocis P. Kocis P. Am J Health Syst Pharm. 2006 Nov 15;63(22):2201-10. doi: 10.2146/ajhp060100. Am J Health Syst Pharm. 2006. PMID: 17090740 Review.
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration, and safety issues related to the use of prasterone are discussed. SUMMARY: Prasterone is a proprietary synthetic dehydroe
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration …
Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA. Heo YA. Drugs Aging. 2019 Aug;36(8):781-788. doi: 10.1007/s40266-019-00693-6. Drugs Aging. 2019. PMID: 31290076
Intravaginal prasterone (Intrarosa()) is a synthetic form of DHEA indicated for the treatment of VVA in postmenopausal women presenting with moderate to severe symptoms in the EU; prasterone is also approved in the USA for the treatment of dyspareunia due to menopau …
Intravaginal prasterone (Intrarosa()) is a synthetic form of DHEA indicated for the treatment of VVA in postmenopausal women presenti …
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É; members of the VVA Prasterone Research Group. Labrie F, et al. Menopause. 2018 Nov;25(11):1339-1353. doi: 10.1097/GME.0000000000001238. Menopause. 2018. PMID: 30358731 Clinical Trial.
OBJECTIVE: The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or …
OBJECTIVE: The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prastero
Prasterone (Intrarosa) for Dyspareunia.
Hayes R, Birch M. Hayes R, et al. Am Fam Physician. 2019 Jan 15;99(2):117-122. Am Fam Physician. 2019. PMID: 30633482 Free article. Review. No abstract available.
Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10mug estradiol on symptoms of vulvovaginal atrophy.
Archer DF, Labrie F, Montesino M, Martel C. Archer DF, et al. J Steroid Biochem Mol Biol. 2017 Nov;174:1-8. doi: 10.1016/j.jsbmb.2017.03.014. Epub 2017 Mar 18. J Steroid Biochem Mol Biol. 2017. PMID: 28323042 Review.
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens (CEE) and estradiol (E(2)) on moderate to severe dyspareunia and/or vaginal dryness. ...Decreases over placebo ranged from 0.35 to 1.21 with …
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens …
Prasterone for vulvar and vaginal atrophy.
[No authors listed] [No authors listed] Drug Ther Bull. 2019 Dec;57(12):185-188. doi: 10.1136/dtb.2019.000034. Epub 2019 Oct 2. Drug Ther Bull. 2019. PMID: 31578208 Review. No abstract available.
Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Portman DJ, Goldstein SR, Kagan R. Portman DJ, et al. Climacteric. 2019 Feb;22(1):65-72. doi: 10.1080/13697137.2018.1535583. Epub 2018 Dec 17. Climacteric. 2019. PMID: 30554531 Review.
The loss of sex steroids (e.g. estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman's general health and produces bothersome physical changes that may interfere with normal sexual and genitourinary functioning. ...Adrenal D …
The loss of sex steroids (e.g. estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman …
Adrenopause.
Nawata H, Yanase T, Goto K, Okabe T, Nomura M, Ashida K, Watanabe T. Nawata H, et al. Horm Res. 2004;62 Suppl 3:110-4. doi: 10.1159/000080509. Horm Res. 2004. PMID: 15539809 Review.
Dehydroepiandrosterone(DHEA) and DHEA-S are steroids that are abundantly produced by the adrenal gland. ...
Dehydroepiandrosterone(DHEA) and DHEA-S are steroids that are abundantly produced by the adrenal gland. ...
Preface.
Litwack G. Litwack G. Vitam Horm. 2018;108:xvii-xviii. doi: 10.1016/S0083-6729(18)30062-1. Vitam Horm. 2018. PMID: 30029739 No abstract available.
16,639 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page